VPH - preDiCT

Now at the end of its three-year mission, the preDiCT project has made major advances in:

• Predicting risk of Torsades-de-Pointes (a dangerous cardiac side effect which is a major focus for drug safety testing);

• Linking together models from subcellular to whole-body scale, to give insight into how a drug’s action on an ion channel can translate to disturbances in heart rhythm;

• Creating an easy-to-use environment for running models, to enable non-expert users to benefit from preDiCT’s techniques.

Beyond the life of the project, our research will continue, including collaborations with GSK (investigating TdP risk stratification), Astra Zeneca (modelling of atrial fibrillation), Johnson&Johnson (modelling for insight into drug actions), and the US FDA (modelling for development of new devices).  The wider Virtual Physiological Human movement is still underway and preDiCT researchers anticipate new collaborations with researchers in our sister-projects and beyond.

Attached to this document, you can find a Guide to Models used by the project, an explanation of the TdP risk prediction technique, and an overview of a meeting with industry regulators convened by the project.

Attachments:

Deliverable 2.2 Guide to Models (May 2011) Final.pdf	[ ]	912 Kb	6/8/2011 09:07
Fletcher et al Regulators Workshop-Drug Safety 2011.pdf	[ ]	436 Kb	6/8/2011 09:13
Mirams et al Cardiovasc Res TdP risk Feb 2011.pdf	[ ]	297 Kb	6/8/2011 09:06